Stephen is an associate in the firm's Corporate practice, resident in the Berwyn office. Stephen advises public and private pharmaceutical, biotechnology, and medical device companies in a broad range of matters, including mergers and acquisitions, joint ventures, divestitures, capital markets transactions, Securities Exchange Act reporting, corporate governance, licensing and collaboration transactions and other strategic transactions. He also represents venture capital and seed-stage investors, emerging companies and entrepreneurs in formations, equity and debt financings, as well as other ongoing strategic matters.
Representative matters may include engagements before joining Troutman Pepper.
Articles + Publications
03.14.24
Ready for the Biotech Bounce Back in 2024?
Firm News
02.28.24
Troutman Pepper Counsels Cagent Vascular in Series C Financing
Firm News
08.09.23
Troutman Pepper Advises Compact Membrane Systems in Oversubscribed Series A Funding Round
Firm News
01.10.23
Troutman Pepper Advises Palvella Therapeutics in Series D Financing
Firm News
12.06.22
Troutman Pepper Counsels iECURE in Series A-1 Financing
Firm News
05.25.22
Troutman Pepper Advises Civic Eagle in Series A Financing